Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab and Anlotinib in Advanced Soft Tissue Sarcoma
NCT05926700Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in soft tissue sarcoma (STS), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Feb 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05926700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05926700.